By Fineline Cube Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259, HKG: 2359), for integrated preparation research and development (R&D) and manufacturing services. This collaboration aims to enhance the efficiency and effectiveness of SanReno’s drug development pipeline.
Comprehensive Services and Accelerated Development
Under the terms of the agreement, WuXi STA will serve as a priority partner for SanReno in the new drug R&D sector. WuXi STA will provide a range of one-stop services, including formulation process development, production, preparation of new drug registration documents, and commercial production for SanReno’s research and pipeline products. This partnership is expected to accelerate the implementation and listing process of SanReno’s existing projects and the development progress of future pipeline projects. The collaboration also encompasses the development of highly active drug formulations. Financial details of the partnership were not disclosed.
SanReno Therapeutics’ Pipeline and Global Reach
SanReno Therapeutics boasts two drug candidates at the global Phase III stage: selective endothelin receptor (ETA) antagonist atrasentan and zigakabart (BION-1301), a monoclonal antibody (mAb) blocking a proliferation-inducing ligand (APRIL). Both candidates are under development to treat IgA nephropathy. SanReno Therapeutics holds the development, manufacturing, and commercialization rights for these drugs in Greater China and Singapore.-Fineline Info & Tech